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mutants (I800M and I800L). In addition,
the yeast assay identified mutations that
convey enhanced sensitivity to inhibitors;
one example is L814C. The mutation
I800L is unique in that it induces a split
phenotype: resistance against some in-
hibitors and enhanced sensitivity against
others. The results obtained with yeast
were validated in mammalian systems:
the mutation-induced changes in catalytic
and signaling activities and in resistance
or sensitivity to inhibitors could be faith-
fully reproduced in human cells, in which
the catalytically active mutants retained
oncogenic potential.
We can derive several lessons from this
study. The resistance mutations identified
in the affinity pocket can guide a preemp-
tive strike. It is probably not too early to
start generating small-molecule inhibitors
that are effective against the I800L and
I800M mutants. The L814C mutant,
showing increased sensitivity to inhibi-
tors, is a potentially useful tool for the
study of isoform-specific functions of
p110a. There are currently no isoform-
specific inhibitors available for p110a.
Therefore, cells carrying a knockin-sensi-
tizing mutation could be used with avail-
able compounds at low enough inhibitor
concentrations to analyze the selective
effects on p110a.
Despite the general structural similari-
ties between kinases, there are sharp
differences between protein and lipid
kinases. A reflection of these differences
is the pronounced intolerance of the PI3K
affinity pocket to mutation. A functional
explanation of this remarkable inflexibility
remains an important goal for future
research.
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Figure 1. Testing for PI3K Inhibitors in
Yeast: The ‘‘Reverse Halo’’ Assay
The two plates contain a lawn of yeast cells that
express p110a and hence fail to grow. A PI3K in-
hibitor spotted on a cellulose disk (orange) diffuses
into the surrounding lawn, inhibits p110a, and re-
stores cell growth (A). A control disk with DMSO
has no effect (B).
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p53 is a pivotal bulwark against cancer, but exactly how it suppresses tumors remains elusive, in part
because itmodulates such diverse biological processes via somany downstreampathways. In a recent issue
of Cell, Godar et al. (2008) now identify another string to p53’s anticancer bow—repression of the CD44
cell-surface glycoproteins that coordinate many attributes of tumor progression.As principal cell factotum of stress respon-
ses, sentinel of damage, guardian of the
genome, and scourge of all cancers, the
p53 protein has assumed an almost myth-108 Cancer Cell 14, August 12, 2008 ª2008ological status. Such remarkable attributes
havegarnered p53 muchattention fromthe
scientific community, and, some 46,581
scientific publications later (as of July 21,Elsevier Inc.2008), one might be forgiven for thinking
that we know all there is to know about
this eldritch protein. Well, actually, no.
There are just a few questions that remain
Cancer Cell
Previewsunanswered. Let’s start with, ‘‘How does
p53 suppress cancer?’’ And when that’s
done, what about why, where, and when?
The problem is that while we know a lot
of potentially tumor-suppressive things
that p53 can do—like growth arrest, repair,
autophagy, and apoptosis—we know em-
barrassingly little about which of these
effector programs is actually responsible
for quelling cancer in any specific instance.
Likewise, many signals can activate p53—
DNA damage and chromatin disruption,
oncogene activation, physical injury, hyp-
oxia, and misfolded proteins, to name but
a few—but we have little idea which of
them is responsible for engaging p53
during the evolution of any specific tumor
type, or when during the protracted
process of tumor evolution such engage-
ment occurs. Does p53 sense some uni-
versal hallmark of tumorigenicity (perhaps
chronic DNA damage or aberrant Myc or
E2F activity), or is it instead activated by
many different triggers that, between
them, encompass the gamut ofaberrations
inevery different type of tumor?Perhaps all
that we can be sure of, given the dire con-
sequences of untimely p53 activation, is
that whatever triggers p53 in cancers is
peculiar to tumor, and not normal, cells.
Transcription factors like p53 make ver-
satile hooks on which evolution can hang
mechanistically diverse processes that,
when coactivated, coordinate complex
biological programs like cell proliferation,
differentiation, and tumor suppression.
Moreover, evolution can refine, elaborate,
or retask such programs by the simple ex-
pedient of appending requisite promoter/
enhancer recognition elements to new
gene targets, and it is the nature of such
programs to evolve ever more complexity
over time. In this context, it is worth noting
that it is very unlikely that primeval p53
started out as a tumor suppressor. p53
is an evolutionarily ancient animal inven-
tion (Nedelcu and Tan, 2007) already en-
sconced in the earliest metazoans, which,
since they were typically small and short-
lived with postmitotic bodies, had no
need for quelling renegade somatic cells.
Probably, p53 initially evolved as a tran-
scriptional coordinator of cellular stress
and damage responses, ensuring consis-
tent development and integrity of the
germline despite the vicissitudes of a ca-
pricious environment. Tumor suppression
is only necessary in large, long-lived or-
ganisms like vertebrates whose compo-nent cells engage in continuous renewal,
accumulating somatic mutations in the
process. p53’s role in preventing cancer
appears to be a highly specialized and
(some might say, given the high incidence
of human cancer) rather shoddy retasking
of p53’s primordial stress and checkpoint
functions. This makeshift evolutionary
legacy is plainly evident in the multiple,
sometimes conflicting, roles played by
mammalian p53. The same p53 that acti-
vates repair and autophagy to ensure
survival and recovery of cells exposed to
repairable damage, transient stress, or
nutrient privation also activates irrevers-
ible arrest and/or death in cells that are
severely or persistently injured. Routing
two diametrically opposing programs
through the same effector is redolent of
that unique brand of unintelligent design
so favored by evolution. Matters are fur-
ther compounded by the fact that basal
p53 (i.e., p53 in the absence of overt acti-
vating signals) regulates key aspects of
cell metabolism (Bensaad and Vousden,
2007; Corcoran et al., 2006), development
(Stiewe, 2007), reproduction (Hu et al.,
2008), and stem cell renewal (Gatza
et al., 2007)—all normal physiological
processes. Such multitasking of p53 inev-
itably entails some suboptimal compro-
mises. While p53 does a reasonable job
of protecting us from cancer, it is also
largely responsible for the devastating
side effects of chemotherapy and radia-
tion exposure (Christophorou et al.,
2006) and perhaps, after a lifetime of duti-
fully culling damaged stem cells, the
depredations of aging (Gatza et al., 2007).
Because p53 is involved in so many dif-
ferent processes, not all p53-activated
genes will be engaged in tumor suppres-
sion, and not all p53-suppressed genes
will be oncogenic. How, then, to parse
which of p53’s target genes specifically
serve tumor suppression? Into this frac-
tious fray jump Godar et al. (2008). Their
discovery that p53 negatively regulates
the protean CD44 cell-surface glycopro-
teins is highly provocative and might indi-
cate a key role for CD44 in tumorigenesis.
But equally, it might reflect a role for CD44
in any of the other things that p53 does—
DNA damage response, metabolism,
development, stem cell renewal, or a com-
bination of some or all of the above.
CD44 is the antigenic moniker for a pro-
tean ensemble of cell-surface transmem-
brane glycoproteins, all generated byCancer Cellalternative splicing of ten central exons
transcribed from a single, highly con-
served gene (Ponta et al., 2003). Whereas
the shortest CD44 isoform is expressed
ubiquitously, the others are variously re-
stricted to different tissues and/or stem
cell compartments. Provocatively, ex-
pression of CD44 (usually its larger iso-
forms) is frequently elevated in epithelial
and some hematopoietic tumors, most
notably in those cell subpopulations that
comprise tumor-initiating cells (Naor
et al., 2008). However, the overexpression
of CD44 in cancer cells is not due to
mutations in the CD44 gene but instead
appears to be due to its induction by
inflammatory cytokines like IL-1b and
osteopontin and by oncogenic signals
such as b-catenin/Tcf-4 and Ras-Raf-
ERK pathways. Ras-Raf-ERK signaling
also modulates CD44 alternative splicing.
Quite how CD44 contributes to malig-
nancy is unclear, because CD44 proteins
participate in a bewildering diversity of bi-
ological processes. They act as receptors
for extracellular matrix components such
as hyaluronic acid, collagen, and fibro-
nectin and interface between epithelial
and endothelial cells through interactions
with L- and E-selectins. They also modu-
late availability of growth-factor receptors
by recruiting matrix metalloproteases to
the extracellular surface and serve as ob-
ligate coreceptors for members of the
EGFR and Met receptor tyrosine kinase
families. The intracellular CD44 effector
domain is similarly multifaceted, interact-
ing directly with a subset of cytoskeletal
components and various intracellular
signaling molecules—most notably the
guanine nucleotide exchange factors
p115RhoGEF and LARG, through which
CD44 activates the RhoA GTPase path-
way, and TIAM1 and Vav2, which engage
the Rho GTPases Rac1 and Cdc42. Be-
tween them, RhoA, Rac1, and Cdc42 are
likely responsible for most of the protu-
morigenic properties of CD44, driving
cell growth and survival, promoting tumor
cell migration and invasion, and facilitat-
ing adhesion of metastatic tumor colonies
to distal stroma and endothelium (Bour-
guignon, 2008).
Godar et al. (2008) start from the sim-
ple correlative observation that CD44 ex-
pression is high in p53-negative mam-
mary epithelial cells and demonstrate
that p53 can directly suppress CD44 via
a p53-responsive element in the CD4414, August 12, 2008 ª2008 Elsevier Inc. 109
Cancer Cell
Previewspromoter. But what does this have to do
with p53-mediated tumor suppression?
More compelling in this regard is their
evidence that CD44 overexpression an-
tagonizes the tumor-suppressive apopto-
tic and growth-inhibitory actions of p53
in mammary epithelial cells and that
tumorigenicity of transformed mammary
epithelial cells requires CD44 derepres-
sion. Taken together, these data strongly
support a critical role for CD44 in tumori-
genesis and the importance for tumor
suppression of its repression by p53.
However, this is unlikely to be the
whole story. Intriguingly, Godar et al.
(2008) also offer evidence that CD44
expression is regulated by basal p53.110 Cancer Cell 14, August 12, 2008 ª2008This intimates that the regulation of CD44
by p53 also plays a part in normal physio-
logical functions. Given the role that CD44
appears to play in various hematopoietic
and epithelial stem cell compartments,
this could be one of the emerging links
between p53 and stem cell self-renewal.
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